[Infostock Daily = Reporter Kim Jong Hyo] Shinhan Investment said on the 12th that Samsung BioLogics has proven its potential for global contract manufacturing organization(CMO) by expanding its fourth plant, adding that we will maintain its 'Buy' investment opinion and raise its target share price to 950,000 won from 870,000 won.
Shinhan Investment said, "The 4-factory production capacity of 25.6 million liters will be renewed the record of Samsung BioLogics' 3 plants, which is the largest global production facility based on a single plant. The investment amount of 1.74 trillion won for the construction of the 4-factory plant is about twice the cost of the 3-factory construction."
"Samsung BioLogics is expected to maintain its position as the largest global CMO company with a total production capacity of 620,000 liters of biopharmaceutical CMO facilities through the expansion of its 4 plants. The operating profit ratio of the company is also expected to rise to the mid-40% range due to a continuous increase in the number of batches "the company added.
Reporter Kim Jong Hyo kei1000@infostock.com
